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Abstract
Background: Incidence rates of advanced cancer stages are important, e.g., for monitoring cancer screening
programs. However, information from cancer registries on tumor stage is often incomplete. Exemplified by
colorectal cancer (CRC), we explored the potential of German claims data to estimate incidence rates of advanced
cancer stages.
Methods: We used claims data of the German Pharmacoepidemiological Research Database (GePaRD; information
on > 20 million persons) to identify incident patients with advanced CRC based on ICD-10 codes for CRC and
secondary malignant neoplasms. We calculated annual age-standardized incidence rates (ASIRs) of advanced CRC
per 100,000 for the years 2008–2015 stratified by the presence of affected lymph nodes only (C77) vs. distant
metastases (C78-C79) and compared them to ASIRs determined using data (2008–2014) from the German Centre
for Cancer Registry Data (ZfKD).
Results: In GePaRD, the ASIRs of advanced CRC per 100,000 in 2014 were 21.5 among men and 14.9 among
women. Compared to ZfKD data the ASIR in GePaRD was 2.58 lower in men and 0.27 higher in women (per 100,
000) in 2014. Stratification by presence of distant metastases showed divergent patterns: the ASIRs regarding distant
metastases were ~ 50% (women) and ~ 30% (men) higher, and the ASIRs regarding affected lymph nodes only
were ~ 40% lower in GePaRD as compared to ZfKD.
Conclusion: While ASIRs of advanced CRCs overall agreed well between claims and cancer registry data in 2014,
the analyses stratified by presence of distant metastases showed differences. Cancer registries might underestimate
ASIRs of CRCs with distant metastases.
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Background
Cancer stage at diagnosis is an essential determinant of
cancer survival [1–5]. While the involvement of regional
lymph nodes is already disadvantageous, patients with
distant metastases have the least favorable prognosis.
For example, regarding the four most common cancers
(i.e. breast, lung, colorectal, and prostate cancer), 5-year
relative survival of patients with distant metastases
ranged between of 5 to 30% as compared to 56 to 100%
for localized stages [6]. The rate of cancers diagnosed
with distant metastases is thus an important parameter
to monitor the cancer burden.
Whereas cancer registries typically show a high level
of completeness regarding cancer incidence, information
on the spread to regional lymph nodes or the presence
of distant metastases is often less complete [1, 2, 7, 8].
In particular, the recording of data on distant metastasis
is problematic for two reasons. First, the diagnostic pro-
cedures may not be completed at the time when the
cancer is reported to the cancer registry. Second, a cer-
tain proportion of cancers may be reported to the cancer
registry by pathologists only who examine the tumor tis-
sue but do not have information on distant metastases.
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Claims databases are an increasingly important data
source in oncology to address research questions where
primary or registry data are limited [9–12]. It needs to
be explored whether they also bear potential to monitor
the rate of advanced colorectal cancer (CRC) stages, par-
ticularly those with distant metastases. For some claims
databases, algorithms to determine cancer stage have
been developed, mainly for breast cancer but partly also
for other cancer sites [9, 11–15]. German claims data
have not been explored in this regard so far. While the
potential of claims data to identify advanced cancers is
of general interest from a methodological point of view,
monitoring the rate of advanced CRC is of particular
interest in Germany due to recent developments in CRC
screening [16]. We therefore aimed to explore the po-
tential of determining the incidence rates of advanced
CRC based on German claims data and to compare
them to rates determined based on cancer registry data,
including trends over time.
Methods
Data sources
We used the German Pharmacoepidemiological Research
Database (GePaRD) for this study. The database is de-
scribed in detail elsewhere [17]. GePaRD is based on
claims data from four statutory health insurance providers
in Germany and currently includes information on more
than 20 million persons who have been insured with one
of the participating providers since 2004 or later. In
addition to demographic data, GePaRD contains informa-
tion on drug dispensations, outpatient and inpatient ser-
vices and diagnoses. Per data year, there is information on
approximately 17% of the general population and all geo-
graphical regions of Germany are represented.
In GePaRD, diagnosis codes are registered according
to the International Statistical Classification of Diseases
and Related Health Problems, 10th revision, German
Modification (ICD-10 GM). For inpatient diagnosis
codes, the exact date is available in German claims data,
while outpatient diagnosis codes are only available on a
quarterly basis. With respect to the inpatient setting, we
considered main and secondary hospital discharge diag-
noses, but not admission diagnoses. In the outpatient
setting, the additional coding of diagnostic certainty is
mandatory in Germany. This coding differentiates be-
tween “confirmed”, “suspected”, “status post” and “ex-
cluded” diagnoses. For the inclusion of incident CRCs,
we only considered diagnoses from the outpatient set-
ting coded as “confirmed”. For the exclusion of prevalent
CRCs both “confirmed” and “status post” diagnoses were
considered as described below.
As additional data source we used data from the Ger-
man Centre for Cancer Registry Data (Zentrum für Krebs-
registerdaten, ZfKD). Data from ZfKD was available for
the years 2008 to 2014. The ZfKD receives data from the
population-based cancer registries collecting data in each
German federal state [18]. The ZfKD estimates the com-
pleteness of reported cancer cases based on the method
recommended by the International Agency for Research
of Cancer (IARC) for each of these registries, using cancer
site specific mortality/incidence ratios of established regis-
tries as a reference [18, 19].
Analyses of GePaRD data
To identify patients diagnosed with advanced CRC and
determine the annual rate, we first needed to identify pa-
tients with an incident CRC diagnosis in a particular cal-
endar year. For this first step, we included all patients
with an in- or outpatient diagnosis code of CRC (C18-
C20) in the respective year. We defined the date of the
first CRC code in this year as cohort entry. We only in-
cluded patients with an additional (in- or outpatient)
diagnosis code for CRC in the same or in the two fol-
lowing quarters (i.e. within up to 6–9 months) after co-
hort entry to confirm the initial diagnosis. To restrict
the sample to incident CRCs, we excluded patients with
a code for CRC (“confirmed” or “status post”) during a
preobservation period of 4 years before cohort entry.
This required excluding patients whose insurance period
was less than 4 years. Further, we excluded patients with
an interruption of insurance of more than 15 days and
patients below 5 years of age. The procedure regarding
the preobservation period and the confirmatory diagno-
sis is in line with a previously developed algorithm to
identify incident CRCs in German claims data [20].
In the second step, we considered information regard-
ing stage at diagnosis of the incident CRC cases. Specif-
ically, we considered codes for lymph node involvement
and metastases (C77-C79) documented in the quarter of
cohort entry or in the following quarter (i.e. within 3–6
months after cohort entry). We categorized patients with
one in- or outpatient diagnosis code of lymph node in-
volvement (C77) or metastases (C78-C79) as patients
with advanced CRC. We also considered these patients
stratified by stage, i.e. those with affected lymph nodes
only (C77), corresponding to UICC III, vs. those with
distant metastases (C78-C79), corresponding to UICC
IV. We conducted sensitivity analyses with varying pe-
riods for considering C78-C79 diagnoses (i.e. up to 0–3
months and 6–9 months after cohort entry instead of up
to 3–6months). Furthermore, we determined the pro-
portion of patients classified as UICC IV for whom at
least one C78–79 diagnosis code was recorded as in-
patient discharge diagnosis. The codes used in the ana-
lyses are listed in Additional file 1.
To roughly assess whether using only diagnostic codes
leads to a substantial underestimation of the number of
advanced CRCs, we considered patients not classified as
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advanced CRC and assessed whether they received a
medical therapy that is typically only administered in ad-
vanced CRC such as Bevacizumab (see Additional file 1).
For this analysis, we used the subsample of CRC patients
of one SHI that provides detailed information on cancer
therapy in the in- and outpatient setting. The remaining
SHIs do not transfer data on specific agents included in
chemotherapies in the outpatient setting.
To estimate the incidence rate of advanced CRC per
year, we used the number of incident CRC cases classi-
fied as “advanced” for the respective year in the nomin-
ator. As denominator, we used the number of all
individuals in GePaRD of the respective year, excluding
those who were not continuously insured during a look-
back period of at least 4 years. This exclusion criterion
ensured comparability between the nominator and the
denominator given that inclusion of CRC patients also
required a look-back period of 4 years. We first deter-
mined the crude rates and then calculated age-
standardized incidence rates (ASIRs) of advanced CRCs
per 100,000 persons [21]. ASIRs were calculated for each
calendar year (2008–2015) and stratified by sex. All
ASIRs presented in this paper are calculated according
to the old European Standard Population [22].
Analyses of ZfKD data
We compared our results based on GePaRD to the inci-
dence rate of advanced CRC determined based on data
of the ZfKD. We included only data from federal state
cancer registries showing an estimated level of complete-
ness of 95% or more with respect to the incidence of
CRC during the whole observation period. This resulted
in the inclusion of seven federal state cancer registries
covering about 32 million inhabitants of Germany (~
39% of the general population). To categorize incident
CRCs according to stage analogously to the approach
applied to the GePaRD, we used information on the
TNM status as far as it was available in the ZfKD data.
The respective algorithm is described in Additional file 2.
For each year we determined the proportion of CRCs
that was not classifiable into these categories due to
missing information on the N- or M-status. When calcu-
lating rates, we used the number of incident CRCs clas-
sified as “advanced” as nominator and the number of
inhabitants of the federal states included in the analysis
as denominator [23, 24]. Analogously to the analysis
based on GePaRD, we calculated ASIRs (also standard-
ized according to the old European Standard Population)
of advanced CRCs per 100,000 persons for each calendar
year (2008–2014) and stratified by sex. We also stratified
the analyses by UICC III vs. IV. We conducted add-
itional analyses regarding the impact of different ap-
proaches how to consider missing information on the N
and M status in ZfKD data (see Additional files 3 and 4).
We conducted all analyses with SAS 9.3 [25].
Results
In Table 1, we show the characteristics of the source
population and the patients identified with advanced CRC
for the years 2008 and 2014. The mean number of patients
with advanced CRC per year was 3081. More than half of
the patients with advanced CRC were male. The mean age
ranged between 68.2 and 70.0 years among female and be-
tween 67.0 and 68.6 years among male patients (Table 1).
In the data from ZfKD, the mean number of patients with
advanced CRC per year was 10,333 (56% male patients).
The mean age among female patients ranged between
70.6 and 71.0 years and among male patients between 67.6
and 68.3 years (Table 1).
Figure 1 shows the ASIRs of advanced CRC deter-
mined based on data from GePaRD and ZfKD, respect-
ively. According to GePaRD data, the ASIR of advanced
CRC decreased from 21.6 to 20.0 in men and from 14.4
to 13.2 per 100,000 in women between 2008 and 2015.
According to ZfKD data, the ASIR of advanced CRC de-
creased from 28.6 to 24.1 in men and from 18.1 to 14.7
per 100,000 in women between 2008 and 2014. In 2014,
the most recent year for which ZfKD data were available,
the ASIR in GePaRD was 2.58 lower in men and 0.27
higher in women (per 100,000) compared to ZfKD.
Figure 2 shows the ASIRs of advanced CRCs stratified
by the presence of affected lymph nodes only, i.e. UICC
III, (Fig. 2a) vs. the presence of distant metastases, i.e.
UICC IV (Fig. 2b) determined based on data from
GePaRD and ZfKD, respectively. Across all years, the
ASIRs of advanced CRCs with affected lymph nodes only
(UICC III) was lower according to GePaRD as compared
to ZfKD. In 2014, the ASIRs were 38% lower in women
and 43% lower in men (Fig. 2a). An opposite pattern was
observed for the ASIRs of advanced CRCs with the pres-
ence of distant metastases (UICC IV). In 2014, the
ASIRs were 52% higher in women and 29% higher in
men according to GePaRD as compared to ZfKD (Fig.
2b). According to GePaRD data, the ASIRs of CRC with
distant metastasis (UICC IV) decreased between 2008
and 2015 from 15.2 to 12.9 in men and from 10.4 to 8.5
per 100,000 in women.
In the sensitivity analyses using varying periods (0–3
and 6–9months after cohort entry) for the consideration
of C78-C79 diagnosis codes, the ASIR of advanced CRCs
with the presence of distant metastases (UICC IV) de-
creased using the shorter period and increased using the
longer period (Fig. 3). For 87.2% of patients classified as
UICC IV in the main analysis, at least one C78–79 diag-
nosis code was recorded as inpatient discharge diagnosis.
For two thirds of the remaining patients, there were two
or more outpatient diagnosis codes (status “confirmed”)
for distant metastasis. With respect to UICC III, extending
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the period from 3 to 6months to 6–9months to consider
C77 diagnoses did not change the respective rates (see
Additional file 5).
Figure 4 shows the results of our approach to assess
whether the algorithm used for the GePaRD data leads
to a substantial underestimation of the number of ad-
vanced CRCs. In a subsample of 4474 CRC patients for
whom detailed information on administered in- and out-
patient medication was available, 2730 were classified as
non-advanced CRCs, i.e. no C77-C79 diagnostics codes
were recorded in these patients. Of these, 16 patients
(0.36%) received medication that is typically only pre-
scribed for advanced CRC.
The results of the additional analyses regarding the
impact of different approaches how to consider missing
information on the N and M status in ZfKD data are de-
scribed in Additional files 3 and 4. As shown in Add-
itional file 2, the proportion of CRCs that were not
classifiable as advanced or non-advanced CRCs accord-
ing to the information on the N and M status in the
ZfKD data decreased from 35 to 29% between 2008 and






















Fig. 1 Age-standardized incidence rates (ASIRs) of advanced CRC: Comparison between claims data (GePaRD) and cancer registry data (ZfKD)
Table 1 Source population and advanced CRC patients identified in claims data (GePaRD) and in cancer registry data (ZfKD):
Distribution of age and sex exemplified for 2008 and 2014
GePaRD ZfKD
2008 2014 2008 2014
Source population
Overall 10,333,691a 11,120,604a 32,114,493 31,784,281
Men (%) 4,596,991 (44.5%) 5,097,709 (45.8%) 15,711,368 (48.9%) 15,563,141 (49.0%)
Women (%) 5,736,700 (55.5%) 6,022,895 (54.2%) 16,403,125 (51.1%) 16,221,140 (51.0%)
Mean age [years] 45.4 47.6 44.4 45.8
Men 44.0 46.2 43.0 44.4
Women 46.5 48.8 45.8 47.1
Advanced CRC patientsb
Overall 2755 3370 10,750 9534
Men (%) 1439 (52.2%) 1764 (52.3%) 5919 (55.1%) 5435 (57.0%)
Women (%) 1316 (47.8%) 1606 (47.7%) 4831 (44.9%) 4099 (43.0%)
Mean age [years] 68.1 69.2 69.0 69.4
Men 67.0 68.6 67.6 68.3
Women 69.3 70.0 70.7 70.9
aPersons with continuous health insurance coverage of at least 4 years
bIn one of the health insurances providing data of about 6 million insured persons to GePaRD, the proportion of women 50 years old or older is substantially
higher as compared to the general population (32.1% vs. 22.5%). This explains why the gender distribution among patients with advanced CRCs differs from the
distribution reported by cancer registries













































Fig. 2 a. Age-standardized incidence rates (ASIRs) of advanced CRCs with affected lymph nodes only: Comparison between claims data (GePaRD)
and cancer registry data (ZfKD). b. Age-standardized incidence rates (ASIRs) of advanced CRCs with distant metastases: Comparison between


















Men - 6-9 months
Men - 3-6 months
Men - 0-3 months
Women - 6-9 months
Women - 3-6 months
Women - 0-3 months
Fig. 3 Sensitivity analyses on age-standardized incidence rates (ASIRs) of advanced CRCs with distant metastases estimated based on claims data
(GePaRD): Comparison of different periods used for the consideration of C78–79 codes after cohort entry
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ASIRs of non-advanced CRCs that were about twice as
high in GePaRD compared to ZfKD, while the ASIRs
converged when we assumed that all non-classifiable
CRCs were non-advanced (see Additional file 3).
The proportion of advanced CRCs that could not fur-
ther be stratified by UICC stage III vs. IV decreased
from 17 to 7% between 2008 and 2014 (see Additional
file 2). When making the extreme assumption that all
advanced CRCs that could not be stratified by UICC
stage III vs. IV based on ZfKD data were exclusively
UICC stage IV, the ASIRs of UICC stage IV CRCs were
still slightly higher in GePaRD compared to ZfKD (see
Additional file 4)b..
Discussion
To the best of our knowledge, this is the first study that
explored the potential of German claims data to estimate
the incidence rate of advanced cancer stages. For ad-
vanced CRC, we found on average 10% lower rates in
women and 17% lower rates in men between 2008 and
2014 when using claims data as compared to cancer
registry data, with a trend towards decreasing differences
in most recent data years. However, stratification by the
presence or absence of distant metastases showed differ-
ent patterns. The rate of CRCs with distant metastases
was markedly higher (on average 26% in men and 40%
in women) when determined based on claims data as
compared to estimates based on cancer registry data,
while for advanced CRCs with affected lymph nodes
only it was the other way round. Given that cancers pre-
senting with distant metastases show the worst progno-
sis, a potential underestimation of their incidence by
cancer registries would be of high relevance and de-
serves further attention.
In the absence of a gold standard, potential limitations of
both data sources need to be discussed and consideration
of complementary patterns may be helpful to approach the
answer regarding the true rates. In epidemiological cancer
registration, a certain proportion of incident cancer cases is
reported by pathologists only who do typically not have in-
formation on distant metastasis, which could lead to an
underestimation of the respective rates. Furthermore, a po-
tential delay in diagnostic procedures needs to be consid-
ered. A scenario where a certain proportion of cancers with
known lymph node status is reported to cancer registries as
“M0” before the procedures to diagnose distant metastases
are completed could be another explanation of the patterns
we observed in our study. These cancers would be assigned
to the category “affected lymph nodes only” based on can-
cer registry data, while claims data would capture metasta-
ses diagnosed or treated after the cancer has been reported
to the cancer registry. The relevance of this scenario is sup-
ported by the results of our sensitivity analyses where the
rates of CRCs with distant metastases were lower when we
Patients with CRC 















Fig. 4 Number of patients classified as patients with non-advanced CRC who received medication typically only administered in patients with
advanced CRCs (in a subsample diagnosed in 2015)
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used a follow-up period of only 3 months for the consider-
ation of diagnosis codes in claims data. Of note, the time
period of getting potential information on distant metasta-
sis inherently differs between cancer registry and claims
data. According to guidelines by the European Network of
Cancer Registries (ENCR) for epidemiological cancer regis-
tration, affected lymph nodes and metastases diagnosed
before start of treatment measures should be assigned to
stage at diagnosis. Thus, the results of delayed diagnostic
procedures may not be reported to cancer registries [26].
The recommendation of the Union for International Can-
cer Control (UICC), which maintains the TNM staging
classification, in terms of abandoning “MX” and assigning
“M0” unless there is positive evidence of metastases could
be relevant regarding both explanations discussed above
[27]. Accordingly, the current system and guidelines of
cancer registration may lead to an underreporting of syn-
chronous metastasis, which are typically defined as metas-
tases diagnosed within 6months after initial cancer
diagnosis [28].
On the other hand, also the information provided by
claims data needs to be questioned given that they are
not primarily collected for research but for the purpose
of reimbursement. However, for more than 85% of per-
sons assigned as CRC patients with distant metastases
based on claims data, an inpatient discharge diagnosis
code for distant metastases was available. In Germany,
inpatient discharge diagnoses are assumed to have a high
validity since they are based on all information relevant
to diagnosis (including laboratory tests and imaging re-
sults) during the in-hospital stay [29]. Furthermore, they
are subject to regular inspections. For the vast majority
of the remaining persons, there was not only one, but at
least two confirmed outpatient diagnosis codes for dis-
tant metastasis. Despite potential advantages of claims
data in recording distant metastasis, the overall pattern
in ASIRs of advanced CRCs suggests that claims data
tend to underestimate the rate of UICC stage III as com-
pared to cancer registry data, possibly due to undercod-
ing of lymph node involvement.
In the interpretation of the rates determined based on
cancer registry data, it needs to be considered that about
30% of incident CRCs across all data years could not be
classified as early or advanced cancers due to missing in-
formation on the N or M status. Still, the rates of ad-
vanced CRCs overall showed good agreement with the
rates determined based on claims data. By contrast, the
rates of non-advanced CRCs showed only good agree-
ment with the rates determined based on claims data
when we assumed that the CRCs with missing stage in-
formation were all non-advanced (see Additional file 3).
This pattern might indirectly show that the vast majority
of CRCs for which cancer registry data did not provide
enough information to classify them as early or
advanced were diagnosed at an early stage, but this re-
mains speculative.
While there is no study from Germany to which we
could compare our findings, there are two studies from
the US that explored the potential of claims data to dis-
tinguish between early and advanced CRCs. For CRCs
classified as metastatic according to an electronic med-
ical record database, Nordstrom et al. found claims
codes for distant metastases in only about 30% of these
cases. However, the follow-up in this study was limited
to 60 days. In addition, in was not clear whether all phy-
sicians providing oncology care to the patients were cap-
tured by the open claims system that was used for this
study [9]. Chawla et al. assessed the potential of Medi-
care claims data for inferring stage at the time of CRC
diagnosis by linking the claims to cancer registry data
from the Surveillance, Epidemiology and End Results
(SEER) program. They aimed to classify CRCs into the
SEER historic stages (local vs. regional vs. distant) which
required – unlike our approach – also information on
the localization of metastases. Diagnosis codes from
Medicare data showed only limited discriminatory power
in this regard, with the misclassification being most pro-
nounced in older CRC patients and in those residing in
lower income areas. Overall, classification based on
Medicare diagnosis codes underestimated the proportion
of regional or distant cancer stages, which differs from
our findings based on German claims data [12]. This
emphasizes that it is not possible to draw generalized
conclusion for claims databases from different countries
due to differences between health systems and reim-
bursement policies influencing the availability and valid-
ity of codes.
Our claims data analyses showed an overall decrease
in the rate of CRCs with distant metastases between
2008 and 2015 by 15% in men and 18% in women. This
decreasing trend was also observed in the most recent
data years. Given the time-lagged association between
incidence of these CRCs and CRC mortality, the pattern
suggests that the current trend of a decreasing CRC
mortality in Germany will continue over the next years
[30]. This decline may have several reasons but it is con-
sidered likely that the introduction of screening colonos-
copy in 2002 in Germany has contributed to this trend.
We recognize both strength and limitations to our
study. The claims database allowed to estimate rates
based on a large sample size and to assess trends over
time. Due to the long follow-up we could use look-back
periods of 4 years which is advantageous in terms of reli-
ably distinguishing incident from prevalent cancers [20].
We could not directly link claims and cancer registry
data, but compared the rates indirectly and conducted
thorough sensitivity analyses to ensure a careful inter-
pretation of the findings. Since the claims data only
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provide diagnosis codes according to ICD-10, we could
not differentiate between affected regional vs. distant
lymph nodes and considered them all as regional. This
leads to a potential misclassification given that the TNM
system assigns affected distant lymph nodes to the M
status. However, if this misclassification could be
avoided the GePaRD-based rates of CRCs with distant
metastasis would be even higher and the difference to
the cancer registry-based rates would thus be even larger
than reported in our study. It should also be noted that
the codes C77-C79 do not carry the information about
the primary tumor. In case of multiple cancer, the dis-
tant metastasis and affected lymph nodes might be
caused by a different type of cancer.
In the interpretation of our study, it should also taken
into account that we did not expect perfect agreement be-
tween the rates determined based on cancer registry ver-
sus claims data given that the study population underlying
the claims data may not be fully representative of the gen-
eral population in Germany. In this context, the differen-
tial agreement by gender requires further exploration.
Overall, our study was not intended to question the value
of population-based cancer registration, especially in view
of the full population coverage and all the information on
cancers (e.g. on histology, tumor size, and grading) that is
not available in claims data. However, determining the rate
of advanced cancer stages based on claims data could
complement cancer registration, e.g. by allowing to inves-
tigate potential determinants of advanced cancer stages
(co-morbidity, etc.).
Conclusions
In conclusion, our study provides important insights into
the potential of German claims data to estimate the inci-
dence rates of advanced cancers. While ASIRs of ad-
vanced CRCs in recent years overall agreed well between
claims and cancer registry data, within the group of ad-
vanced CRCs cancer registries might underestimate
ASIRs of CRCs with distant metastases when lymph
node involvement is present. This requires further con-
sideration given that cancers presenting with distant me-
tastases show the poorest survival. Amongst others,
their misclassification would bias stage-specific survival
estimates and underestimating the incidence of these
cancers would bias projections regarding the impact of
cancer screening programs on disease-specific mortality.
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